More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$644782096
EPS
-2.37
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.128073
Previous close
$7.56
Today's open
$7.48
Day's range
$7.08 - $7.73
52 week range
$6.24 - $36.26
show more
CEO
Sean P. Bohen
Employees
150
Headquarters
South San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
87606263
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Olema Oncology, Inc. (OLMA) Olema Pharmaceuticals, Inc. Presents at UBS Global Biopharma Conference 2026 Transcript
Olema Oncology, Inc. ( OLMA ) Olema Pharmaceuticals, Inc. UBS Global Biopharma Conference 2026 November 17, 2026 10:20 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division Well, thank you, everyone. Good afternoon.
Seeking Alpha • 9 hours ago

Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
GlobeNewsWire • Nov 16, 2026

Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Laura Prendergast Stifel, Nicolaus & Company, Incorporated, Research Division Thanks, everyone. Sean, thank you very much for being here.
Seeking Alpha • Nov 12, 2026

Olema Oncology Announces Corporate Name Change
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” pursuant to the Company's Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.
GlobeNewsWire • Nov 12, 2026

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 10, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to ten new employees to purchase an aggregate of 261,300 shares of the Company's common stock, effective as of November 2, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
GlobeNewsWire • Nov 3, 2026

Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
GlobeNewsWire • Nov 2, 2026

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
Zacks Investment Research • Oct 16, 2026

Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha • Sep 15, 2026

Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha • Sep 10, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Olema Oncology Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.